

中国临床前和毒性研究外包:现状分析与前景预测

Future Outlook of China Preclinical and Toxicology Outsourcing Market



Table of Contents

Scope of the Report

About Author

Executive Summary

- ◆ Growing importance of preclinical and toxicology research in drug discovery and development
- ◆ Preclinical and toxicology outsourcing nears mature in China
- ◆ Current service capability and capacity of Chinese preclinical and toxicology outsourcing industry
- ◆ Future outlook of preclinical and toxicology outsourcing in China

Chapter One: Growing Importance of Preclinical and Toxicology Research in Drug Discovery and Development

Summary

- 1.1 Introduction
- 1.2 Drug safety has become the bottleneck limiting drug R&D productivity
 - 1.2.1 Cost and efficiency of drug R&D have become key concerns to all drug companies
 - 1.2.2 In-depth analysis of the causes of high failure rate in drug R&D
 - 1.2.3 Reducing attrition rate and improving R&D productivity have become high priority to all drug companies
- 1.3 Changing models of drug R&D spending
 - 1.3.1 New trend: Less R&D budget but more positive results have become high priorities to all drug companies
 - 1.3.2 More R&D budget is being reallocated to preclinical and toxicology research
 - 1. Analysis of the cost structure of entire drug R&D process
 - 2. Reallocating more R&D budget to preclinical and toxicology research
- 1.4 Development of new technologies to more precisely probe toxicity of drug candidates
- 1.5 Global major CROs developing new outsourcing services
- 1.6 Evolving of new trends in preclinical and toxicology outsourcing
 - 1.6.1 New outsourcing models
 - 1. Contracting out a whole block of R&D functions
 - 2. Networked Partnership
 - 3. Open source innovation
 - 1.6.2 Destination of preclinical and toxicology outsourcing is shifting toward the East

Chapter Two: Preclinical and Toxicology Outsourcing in China Nears Mature

Summary

- 2.1 Introduction
- 2.2 Preclinical and toxicology outsourcing in China: A short history
- 2.3 Preclinical and toxicology outsourcing service is fast developing in China
 - 2.3.1 Rapid growth of the CRO pool in China
 - 2.3.2 Extremely fast growth of Chinese preclinical and toxicology outsourcing market
- 2.4 Rapid improvement of service capability of Chinese CROs in preclinical and toxicology research
- 2.5 China has formally established a regulatory body for preclinical research and is rapidly enhancing its capability
- 2.6 Growing importance of China to drug companies around the world for preclinical and toxicology research
 - 2.6.1 China's advantages in preclinical research
 - 1. Abundant animal species
 - 2. Large, well-trained workforce
 - 3. Cost effective advantage
 - 2.6.2 New development trends of preclinical and toxicology outsourcing in China – Entrance of growing numbers of multinational CROs: A series of case studies
- 2.7 Major pharma companies starting outsourcing preclinical and toxicology research in China
 - 2.7.1 Motivations of major pharma companies outsourcing preclinical and toxicology research to China
 - 2.7.2 Case studies: Latest examples of outsourcing and research collaborations between major pharma companies and Chinese companies/research organizations
- 2.8 Time to outsource preclinical and toxicology research to China nears mature

Chapter Three: Current Service Capability and Capacity of Chinese Preclinical and Toxicology Outsourcing Industry

Summary

- 3.1 Introduction
- 3.2 Current key players of Chinese preclinical and toxicology outsourcing industry
- 3.3 Service capability of China-based CROs
 - 3.3.1 Description of general service capability of China-based CROs
 - 1. General description of research scopes of modern preclinical and toxicology studies
 - a. Different focuses between preclinical and toxicology study
 - b. Main focuses of modern toxicology research
 - c. Difference and similarity between toxicology and safety pharmacology research
 - 2. General service capability of China-based CROs
 - 3.3.2 Service capability of China-based CROs in *in vitro/in vivo* ADME/Tox studies
 - 3.3.3 Service capability of China-based CROs in *in vivo* drug efficacy determination
 - 3.3.4 Service capability of China-based CROs in other related research areas

- 3.4 Current facility and capacity of China-based CROs
 - 3.4.1 General features of the facilities of China-based CROs
 - 3.4.2 Animal disease models offered by China-based CROs

Chapter Four: Future Outlook of Preclinical and Toxicology Outsourcing in China

Summary

4.1 Introduction

4.2 Future growth drivers of Chinese preclinical and toxicology outsourcing service industry

4.2.1 Internal drivers

1. China will still possess numerous advantages in preclinical and toxicology outsourcing before 2015
2. Improved service capability and quality
3. Government support
4. Entrance of world major CROs
5. Growing demands for outsourcing service by local domestic Chinese drug companies

4.2.2 External drivers

1. Strong demands by major pharma companies for preclinical and toxicology outsourcing
 - a. Globally, outsourcing demands for drug R&D especially preclinical and toxicology research service will become stronger – Analysis on latest outsourcing strategies implemented by major pharma companies
 - b. Regionally, outsourcing demands for Chinese preclinical and toxicology research service by major pharma companies will also become stronger
2. Strong outsourcing demands by small biotech companies for preclinical and toxicology research service

4.3 Future growth resistors

4.4 Forecast of future development patterns of Chinese preclinical and toxicology outsourcing industry

4.4.1 More competition

4.4.2 More consolidation

4.5 Future market growth forecast of Chinese preclinical and toxicology outsourcing industry

4.5.1 Future market growth forecast of Chinese preclinical and toxicology outsourcing industry

4.5.2 Comparison with global market

4.5.3 Comparison with Indian market

Company Profile: Top 30 China-based Best CROs Providing Preclinical and Toxicology Research Service

Appendix

Appendix I. Research Methodology
Appendix II. About JZMed, Inc.

List of Tables

- Table 1. Statistic distribution of failure rate in each development stage of drug R&D
Table 2. Factors contributing to high failure rates in drug development
Table 3. Global drug R&D spending in the past five years (2005 to 2009)
Table 4. Cost analysis of each development stage of drug R&D process
Table 5. Benefits of reallocating drug R&D budget to preclinical and toxicology research
Table 6. China-based CROs (or research organizations) accredited by AAALAC
Table 7. Classifications and features of China-based preclinical and toxicology CROs
(Including representative companies of each class)
Table 8. Current market value and its growth history of Chinese preclinical and toxicology outsourcing service industry
Table 9. Current market value and growth history of global preclinical and toxicology outsourcing service industry
Table 10. Growth of the market share of Chinese preclinical and toxicology outsourcing industry in the market value of global preclinical and toxicology outsourcing industry
Table 11. Representative Chinese organizations that have obtained GLP certificate from the SFDA
Table 12. China's advantages in preclinical and toxicology research
Table 13. Comparison of labor cost in various locations of the world (FTE rate)
Table 14. Comparison of feasibility and advantages between conducting small molecule drug discovery and preclinical/toxicology research in China
Table 15. List of top 30 best CROs in Chinese preclinical and toxicology outsourcing industry
Table 16. Founder classification of top 30 China-based best CROs
Table 17. Detailed description of research scopes of preclinical and toxicology studies
Table 18. Scope of modern *in vitro* and *in vivo* toxicology research
Table 19. Type of preclinical and toxicology research services offered by China-based CROs
Table 20. Key service features of each selected top CRO in China
Table 21. List of selected top China-based CROs and their detailed services in *in vitro/in vivo* DMPK/ADME studies
Table 22. List of selected top China-based CROs and their services in toxicology study
Table 23. List of selected top China-based CROs offering safety pharmacology service
Table 24. List of selected top China-based CROs and their services in *in vivo* efficacy testing
Table 25. List of selected top China-based CROs and their services in *in vivo* pharmacology
Table 26. List of China-based CROs and their services in *in vitro* biological assays
Table 27. List of China-based CROs providing bio-analytical services
Table 28. List of China-based CROs providing biomarker-related services
Table 29. Key features of the selected top China-based CROs' facilities

- Table 30. Current animal space capacity of selected top China-based CROs
- Table 31. List of China-based CROs possessing special animal disease models
- Table 32. Advantages China will still possess before 2015
- Table 33. Comparison of labor cost in countries around the world in the next seven years (FTE rate)
- Table 34. Comparison of cost saving (%) between China and other countries (at present and by 2015)
- Table 35. Market growth forecast of Chinese preclinical and toxicology outsourcing service industry
- Table 36. Market growth forecast of global preclinical and toxicology outsourcing industry
- Table 37. Forecasted growth of the market share of Chinese preclinical and toxicology outsourcing service industry in the same industry of the globe
- Table 38. Market growth forecast of Indian preclinical and toxicology outsourcing service industry and comparison with its Chinese counterpart

List of Figures

- Figure 1. Value chain of drug discovery and development
- Figure 2. Driving factors forcing the toxicology research moved to discovery and early development stages
- Figure 3. New technology development trends in preclinical and toxicology research
- Figure 4. Market growth trend of Chinese preclinical and toxicology outsourcing service industry
- Figure 5. Market growth trend of global preclinical and toxicology outsourcing service industry
- Figure 6. Key factors that facilitated Chinese preclinical and toxicology outsourcing service industry to weather the current financial crisis
- Figure 7. Key factors attracting drug companies to conduct preclinical and toxicology research in China
- Figure 8. Motivations of major pharma companies outsourcing preclinical and toxicology research to China
- Figure 9. Outsourcing strategies and practices currently implemented by major pharma companies in China
- Figure 10. Comparison of labor cost increase in China with other countries (from 2009 to 2015)
- Figure 11. Cost saving comparison (%) between China and other countries (in 2010 and 2015, respectively)
- Figure 12. Government plans to promote Chinese biopharma industry
- Figure 13. Impacts of the latest mergers and acquisitions between experienced multinational CROs and their Chinese counterparts on the future development of Chinese preclinical and toxicology outsourcing service industry
- Figure 14. Factors motivating major pharma companies to pursue more outsourcing in drug discovery, preclinical and toxicology research
- Figure 15. Current development trend of global small molecule drug discovery outsourcing

- Figure 16. Current R&D situation of major pharma companies in China
- Figure 17. Analysis of the future outsourcing demands for Chinese preclinical and toxicology research service by major pharma companies
- Figure 18. Forecasted market growth trend of Chinese preclinical and toxicology outsourcing service industry
- Figure 19. Forecasted market growth trend of global preclinical and toxicology outsourcing service industry
- Figure 20. Forecasted market share growth of Chinese preclinical and toxicology outsourcing industry in global preclinical and toxicology outsourcing industry
- Figure 21. Forecasted market growth trend of Indian preclinical and toxicology outsourcing service industry

List of Case Studies

- Case Study 1. Drug R&D would not be that costly if failure rate could be reduced
- Case Study 2. Biomarkers have become a hot outsourcing area in toxicology research
- Case Study 3. Molecular imaging also becoming an important tool in preclinical as well as toxicology research
- Case Study 4. Growing importance of epigenomics in assessment of drug safety and drug-induced toxicity
- Case Study 5. Major CROs all embarked on biomarker service
- Case Study 6. Charles River expanding discovery service
- Case Study 7. Partnership formed to promote predictive toxicology service
- Case Study 8. Alliance formed to develop drug toxicity screening assays
- Case Study 9. Examples of major pharma companies increasingly utilizing external resources
- Case Study 10. Examples of Western pharma companies outsourcing preclinical and toxicology research to Asian countries
- Case Study 11. A unique class of workforce in China: Chinese returnees and its current state
- Case Study 12. Frontier Biosciences entered Chinese market
- Case Study 13. Bridge Lab established, expanded and eventually sold its China division
- Case Study 14. Charles River entering Chinese market through acquiring a local Chinese CRO and currently aggressively looking for expansion
- Case Study 15. Covance planning to offer preclinical outsourcing service in China
- Case Study 16. Astra-Zeneca outsourcing preclinical and toxicology research to Chinese CROs
- Case Study 17. Astra-Zeneca expanded discovery contract with BioDuro
- Case Study 18. Pfizer signed *in vitro* ADME/Tox outsourcing contract with WuXi AppTec
- Case Study 19. Johnson & Johnson forging close relationship with WuXi AppTec
- Case Study 20. Attempted acquisition of WuXi AppTec by Charles River
- Case Study 21. More recent merger and acquisition examples between Chinese CROs and their multinational counterparts
- Case Study 22. Domestic Chinese drug companies increasingly collaborating with local CROs for drug R&D

- Case Study 23. Examples of pharma company outsourcing all drug discovery research
- Case Study 24. Global pharmaceutical outsourcing: An outlook of its future development
- Case Study 25. Major pharma companies have now recognized the power and usefulness of the large talent pool in China
- Case Study 26. More R&D-focused biotech companies adopting virtual operation model
- Case Study 27. Merger between two Chinese CROs
- Case Study 28. Alliance formed between two China-based CROs
- Case Study 29. Indian CROs' capability in preclinical and toxicology outsourcing service